Response of extraabdominal desmoid tumors to therapy with imatinib mesylate
dc.contributor.author | Mace, Joseph | en_US |
dc.contributor.author | Sybil Biermann, J. | en_US |
dc.contributor.author | Sondak, Vernon K. | en_US |
dc.contributor.author | Mcginn, Cornelius J. | en_US |
dc.contributor.author | Hayes, Curtis W. | en_US |
dc.contributor.author | Thomas, Dafydd G. | en_US |
dc.contributor.author | Baker, Laurence H. | en_US |
dc.date.accessioned | 2006-04-19T13:30:45Z | |
dc.date.available | 2006-04-19T13:30:45Z | |
dc.date.issued | 2002-12-01 | en_US |
dc.identifier.citation | Mace, Joseph; Sybil Biermann, J.; Sondak, Vernon; McGinn, Cornelius; Hayes, Curtis; Thomas, Dafydd; Baker, Laurence (2002)."Response of extraabdominal desmoid tumors to therapy with imatinib mesylate." Cancer 95(11): 2373-2379. <http://hdl.handle.net/2027.42/34360> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34360 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12436445&dopt=citation | en_US |
dc.description.abstract | BACKGROUND Desmoid tumor represents a rare monoclonal neoplasm arising from deep musculoaponeurotic structures and may occur sporadically or in association with the familial adenomatous polyposis and Gardner syndromes. Desmoid tumors do not appear to demonstrate metastatic potential; however, local infiltrative growth results in significant morbidity and potential mortality. Although the delineation of optimal therapy for desmoid tumors has been confounded by several factors, surgical resection with adjuvant radiotherapy for a positive surgical margin remains the standard approach. Responses have been demonstrated to nonsteroidal antiinflammatory agents, antiestrogen compounds, and a variety of other agents in small series. Imatinib mesylate appears to demonstrate inhibitory activity against multiple class 3 receptor tyrosine kinases, including platelet-derived growth factor receptor (PDGFR)-Α and PDGFR-Β, as well as c- kit . METHODS The authors performed immunohistochemical and qualitative real-time polymerase chain reaction analysis on nine desmoid tumor specimens that demonstrated consistent positivity for c- kit as well as PDGFR-Α and PDGFR-Β. At the time of last follow-up, 2 patients had received therapy with imatinib mesylate at a dose of 400 mg twice daily. RESULTS Both patients demonstrated ongoing radiographic and clinical responses with a duration of 9 months and 11 months, respectively. CONCLUSIONS Imatinib mesylate has been reported to have activity against desmoid tumor, most likely because of c- kit and PDGFR receptor tyrosine kinase activity inhibition, and warrants further study. The relative novelty of this agent and the lack of long-term toxicity data should prompt its use only in the salvage setting in which established local and systemic approaches fail to control disease. In addition, the use of imatinib mesylate in the treatment of this neoplasm preferably should be in the context of a formal prospective clinical trial. Cancer 2002;95:2373–9. © 2002 American Cancer Society. DOI 10.1002/cncr.11029 | en_US |
dc.format.extent | 686534 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Response of extraabdominal desmoid tumors to therapy with imatinib mesylate | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Medical Oncology, Department of Internal Medicine, University of Michigan Medical Center, Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Orthopedic Surgery, University of Michigan Medical Center, Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Surgical Oncology, Department of Surgery, University of Michigan Medical Center, Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan Medical Center, Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Radiology, University of Michigan Medical Center, Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Anatomic Pathology, University of Michigan Medical Center, Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Medical Oncology, Department of Internal Medicine, University of Michigan Medical Center, Comprehensive Cancer Center, Ann Arbor, Michigan ; Fax: (934) 936-7376 ; Division of Hematology/Oncology, University of Michigan, 1500 East Medical Center Drive, 7216 CCGC, Ann Arbor, MI 48109-0948 | en_US |
dc.identifier.pmid | 12436445 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34360/1/11029_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.11029 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.